Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options

Human papillomavirus and Herpes simplex virus are the most common genital viral infections encountered in clinical practice worldwide. We reviewed the literature focusing on new and experimental treatment modalities for both conditions, based on to the evidence‐based data available. The modalities evaluated include topical agents such as immune response modifiers (imiquimod, resiquimod, and interferon), antivirals (penciclovir, cidofovir, and foscarnet), sinecatechins, microbiocidals (SPL7013 gel, and PRO 2000 gel), along with experimental (oligodeoxynucleotides), immunoprophylactic, and immunotherapeutic vaccines.

[1]  Joelle M. Brown,et al.  A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days , 2011, PloS one.

[2]  Y. Jacob,et al.  The EVER Proteins as a Natural Barrier against Papillomaviruses: a New Insight into the Pathogenesis of Human Papillomavirus Infections , 2009, Microbiology and Molecular Biology Reviews.

[3]  A. Bruckner,et al.  Epidermodysplasia verruciform-like Lesions in an HIV patient. , 2009, Dermatology online journal.

[4]  H. Kamino,et al.  Epidermodysplasia verruciformis in the setting of HIV infection. , 2008, Dermatology online journal.

[5]  Diane Solomon,et al.  Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. , 2008, Vaccine.

[6]  Veregen: A Botanical for Treatment of Genital Warts , 2008, The Medical letter on drugs and therapeutics.

[7]  A. Katsambas,et al.  Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts , 2008, International journal of STD & AIDS.

[8]  T. Warren,et al.  An International, Randomized, Double-Blind, Placebo-Controlled, Study of Valacyclovir for the Suppression of Herpes Simplex Virus Type 2 Genital Herpes in Newly Diagnosed Patients , 2008, Sexually transmitted diseases.

[9]  K. Beutner,et al.  Sinecatechins, a Defined Green Tea Extract, in the Treatment of External Anogenital Warts: A Randomized Controlled Trial , 2008, Obstetrics and gynecology.

[10]  A. Gewirtzman,et al.  Epidermodysplasia verruciformis and human papilloma virus , 2008, Current opinion in infectious diseases.

[11]  A. Wald,et al.  One-Day Regimen of Valacyclovir for Treatment of Recurrent Genital Herpes Simplex Virus 2 Infection , 2008, Sexually transmitted diseases.

[12]  Chien-Fu Hung,et al.  Therapeutic human papillomavirus vaccines: current clinical trials and future directions , 2008, Expert opinion on biological therapy.

[13]  A. Gottlieb,et al.  New viral vaccines for dermatologic disease. , 2008, Journal of the American Academy of Dermatology.

[14]  N. Dupin,et al.  Study of persistence and recurrence rates in 106 patients with condyloma and intraepithelial neoplasia after CO2 laser treatment. , 2008, European journal of dermatology : EJD.

[15]  Y. Jacob,et al.  Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses , 2007, The Journal of experimental medicine.

[16]  L. Villa.  Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[17]  D. Ferris,et al.  Effect of Resiquimod 0.01% Gel on Lesion Healing and Viral Shedding When Applied to Genital Herpes Lesions , 2007, Antimicrobial Agents and Chemotherapy.

[18]  B. Monk,et al.  The spectrum and clinical sequelae of human papillomavirus infection. , 2007, Gynecologic oncology.

[19]  E. Rutland,et al.  Has episodic treatment of recurrent genital herpes come of age? , 2007, International journal of STD & AIDS.

[20]  M. Gottschling,et al.  Human Papillomaviruses and Non-Melanoma Skin Cancer: Basic Virology and Clinical Manifestations , 2007, Disease markers.

[21]  J. Sherrard,et al.  Comparison of the effectiveness of commonly used clinic-based treatments for external genital warts , 2007, International journal of STD & AIDS.

[22]  O. Himmetoğlu,et al.  Therapeutic value of trichloroacetic acid in the treatment of isolated genital warts on the external female genitalia. , 2007, The Journal of reproductive medicine.

[23]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[24]  A. Wald,et al.  Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. , 2007, The Journal of infectious diseases.

[25]  Vincent Foulongne,et al.  Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. , 2007, The New England journal of medicine.

[26]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[27]  T. Lenz,et al.  Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. , 2006, European journal of dermatology : EJD.

[28]  H. Handsfield,et al.  Suppressive Therapy With Valacyclovir in Early Genital Herpes: A Pilot Study of Clinical Efficacy and Herpes-Related Quality of Life , 2006, Sexually transmitted diseases.

[29]  T. Warren,et al.  Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial. , 2006, Mayo Clinic proceedings.

[30]  S. Ofner,et al.  A Comparison of One Year of Episodic or Suppressive Treatment of Recurrent Genital Herpes With Valacyclovir , 2006, Sexually transmitted diseases.

[31]  Fujie Xu,et al.  Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. , 2006, JAMA.

[32]  James B. Hill,et al.  Valacyclovir Prophylaxis to Prevent Recurrent Herpes at Delivery: A Randomized Clinical Trial , 2006, Obstetrics and gynecology.

[33]  J. Molina,et al.  Topical imiquimod for recurrent acyclovir-resistant HSV infection. , 2006, The American journal of medicine.

[34]  W. Andrews,et al.  Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. , 2006, American journal of obstetrics and gynecology.

[35]  K. Rosenthal,et al.  Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848). , 2006, Antiviral research.

[36]  Mona M. Soliman,et al.  Treatment of genital warts in males by pulsed dye laser , 2006, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[37]  A. Adimora,et al.  The Relationship between Condom Use and Herpes Simplex Virus Acquisition , 2005, Annals of Internal Medicine.

[38]  H. Davis,et al.  TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). , 2005, Vaccine.

[39]  F. Aoki,et al.  Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[41]  B. Herold,et al.  Topical microbicides for the prevention of genital herpes infection. , 2005, The Journal of antimicrobial chemotherapy.

[42]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[43]  A. Wald,et al.  Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. , 2004, The Journal of infectious diseases.

[44]  A. Wald,et al.  Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. , 2004, The Journal of infectious diseases.

[45]  L. Stanberry.  Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. , 2004, Herpes : the journal of the IHMF.

[46]  O. Arican,et al.  Topical Imiquimod 5% Cream in External Anogenital Warts: A Randomized, Double‐Blind, Placebo‐Controlled Study , 2004, The Journal of dermatology.

[47]  L. Aurelian.  Herpes Simplex Virus Type 2 Vaccines: New Ground for Optimism? , 2004, Clinical Diagnostic Laboratory Immunology.

[48]  J. Bartlett,et al.  Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes , 2004 .

[49]  S. Sacks.  Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. , 2004, The Journal of infectious diseases.

[50]  E. Andrews,et al.  Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. , 2004, Birth defects research. Part A, Clinical and molecular teratology.

[51]  J. Berkhof,et al.  Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial , 2003, International journal of cancer.

[52]  A. Ashkar,et al.  Parameters of CpG oligodeoxynucleotide‐induced protection against intravaginal HSV‐2 challenge , 2003, Journal of medical virology.

[53]  R. Pyles,et al.  Immunostimulatory CpG treatment for genital HSV-2 infections. , 2003, The Journal of antimicrobial chemotherapy.

[54]  James B. Hill,et al.  Acyclovir Prophylaxis to Prevent Herpes Simplex Virus Recurrence at Delivery: A Systematic Review , 2003, Obstetrics and gynecology.

[55]  S. Tyring,et al.  Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials , 2003, Journal of cutaneous medicine and surgery.

[56]  Edwin DeJesus,et al.  Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.

[57]  J. Vieira,et al.  Local Delivery of CpG Oligodeoxynucleotides Induces Rapid Changes in the Genital Mucosa and Inhibits Replication, but Not Entry, of Herpes Simplex Virus Type 2 , 2003, Journal of Virology.

[58]  I. Byren,et al.  Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts , 2003, Sexually transmitted infections.

[59]  R. Snoeck,et al.  Topical Cidofovir (HPMPC) Is an Effective Adjuvant to Surgical Treatment of Anogenital Condylomata Acuminata , 2003, Diseases of the colon and rectum.

[60]  K. Shah,et al.  Condyloma in Pregnancy Is Strongly Predictive of Juvenile‐Onset Recurrent Respiratory Papillomatosis , 2003, Obstetrics and gynecology.

[61]  B. Romanowski,et al.  Patients’ Preference of Valacyclovir Once-Daily Suppressive Therapy Versus Twice-Daily Episodic Therapy for Recurrent Genital Herpes: A Randomized Study , 2003, Sexually transmitted diseases.

[62]  L. Corey,et al.  A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. , 2003, American journal of obstetrics and gynecology.

[63]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[64]  J. Holmgren,et al.  A Protective Role of Locally Administered Immunostimulatory CpG Oligodeoxynucleotide in a Mouse Model of Genital Herpes Infection , 2003, Journal of Virology.

[65]  H. Wulf,et al.  Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir , 2002, Sexually transmitted infections.

[66]  L. Stanberry,et al.  Use of Immunostimulatory Sequence-Containing Oligonucleotides as Topical Therapy for Genital Herpes Simplex Virus Type 2 Infection , 2002, Journal of Virology.

[67]  G. Burg,et al.  CO2 Laser Surgery for Extensive, Cauliflower-Like Anogenital Condylomata acuminata: Retrospective Long-Term Study on 19 HIV-Positive and 45 HIV-Negative Men , 2002, Dermatology.

[68]  J. Burnett,et al.  A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. , 2002, Cutis.

[69]  Zengri J. Wang,et al.  Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled Study , 2002, Antimicrobial Agents and Chemotherapy.

[70]  R. Greenblatt,et al.  The Impact of HIV Infection and Immunodeficiency on Human Papillomavirus Type 6 or 11 Infection and on Genital Warts , 2002, Sexually transmitted diseases.

[71]  S. Trottier,et al.  Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  Lawrence Corey,et al.  Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  G. de Panfilis,et al.  Relapses After Treatment of External Genital Warts Are More Frequent in HIV-Positive Patients Than in HIV-Negative Controls , 2002, Sexually transmitted diseases.

[74]  T. Schacker,et al.  Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials , 2002, International journal of STD & AIDS.

[75]  J. Weinberg,et al.  Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. , 2001, Archives of dermatology.

[76]  A. Wald,et al.  Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. , 2001, JAMA.

[77]  D. Luton,et al.  Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[78]  J. Ortonne,et al.  Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel‐groups, randomized, double‐blind clinical trial , 2001, The British journal of dermatology.

[79]  L. Aurelian,et al.  A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. , 2001, Vaccine.

[80]  GW Pearson,et al.  Topical imiquimod , 2001, The Journal of dermatological treatment.

[81]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[82]  Z. P. Guo,et al.  A comparison of topical application of penciclovir 1% cream with acyclovir 3% cream for treatment of genital herpes: a randomized, double-blind, multicentre trial , 2000, International journal of STD & AIDS.

[83]  M. Stanley,et al.  Correlation between Pretreatment Levels of Interferon Response Genes and Clinical Responses to an Immune Response Modifier (Imiquimod) in Genital Warts , 2000, Antimicrobial Agents and Chemotherapy.

[84]  F. Aoki,et al.  Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals , 2000 .

[85]  C. Lacey,et al.  European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts , 2000, Sexually transmitted infections.

[86]  A. Wald,et al.  Herpes simplex virus: the importance of asymptomatic shedding. , 2000, The Journal of antimicrobial chemotherapy.

[87]  R. Miller,et al.  Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. , 1999, Antiviral research.

[88]  J. Stoker,et al.  The Department of Health and Human Services. , 1999, Home healthcare nurse.

[89]  U. Hengge,et al.  Recurrent urogenital herpes simplex--successful treatment with imiquimod? , 1999, Sexually transmitted infections.

[90]  A. Wald,et al.  Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology , 1999, Clinical Microbiology Reviews.

[91]  S. Trottier,et al.  A Multicenter Phase I/II Dose Escalation Study of Single-Dose Cidofovir Gel for Treatment of Recurrent Genital Herpes , 1998, Antimicrobial Agents and Chemotherapy.

[92]  S. Shafran,et al.  Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. , 1998, JAMA.

[93]  L. Corey,et al.  Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. , 1998, The Journal of infectious diseases.

[94]  S. Jabłońska,et al.  Recombinant Interferon Beta Gel as an Adjuvant in the Treatment of Recurrent Genital Warts: Results of a Placebo-Controlled Double-Blind Study in 120 Patients , 1998, Dermatology.

[95]  S. Tyring,et al.  Imiquimod, a Patient-Applied Immune-Response Modifier for Treatment of External Genital Warts , 1998, Antimicrobial Agents and Chemotherapy.

[96]  A. Wald,et al.  Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. , 1997, The Journal of infectious diseases.

[97]  S. Lee,et al.  A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. , 1997, The Journal of infectious diseases.

[98]  J. Bornstein,et al.  Recombinant human interferon- for condylomata acuminata: a randomized, double-blind, placebo-controlled study of intralesional therapy , 1997, International journal of STD & AIDS.

[99]  S. Ahmad,et al.  Human Leukocyte Interferon‐α in a Hydrophilic Cream versus in a Gel for the Treatment of Genital Herpes in Males: A Placebo‐Controlled, Double‐Blind, Comparative Study , 1997, The Journal of dermatology.

[100]  K. Fife,et al.  Valaciclovir Versus Acyclovir in the Treatment of First‐Episode Genital Herpes Infection: Results of an International, Multicenter, Double‐Blind, Randomized Clinical Trial , 1997, Sexually transmitted diseases.

[101]  G. Wilbanks,et al.  The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial , 1997, Medical Microbiology and Immunology.

[102]  S. Jones,et al.  Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study. , 1997, Genitourinary medicine.

[103]  J. Paavonen,et al.  Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. , 1997, Genitourinary medicine.

[104]  N. Bodsworth,et al.  Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. , 1997, Genitourinary medicine.

[105]  M. Loveless,et al.  Oral Famciclovir for Suppression of Recurrent Genital Herpes Simplex Virus Infection in Women: A Multicenter, Double-Blind, Placebo-Controlled Trial , 1997 .

[106]  M. Loveless,et al.  Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. , 1997, Archives of internal medicine.

[107]  S. Tyring,et al.  A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. , 1996, Archives of internal medicine.

[108]  S. Spruance,et al.  A Large-Scale, Placebo-Controlled, Dose-Ranging Trial of Peroral Valaciclovir for Episodic Treatment of Recurrent Herpes Genitalis , 1996 .

[109]  F. Aoki,et al.  Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. , 1996, JAMA.

[110]  A. Mastrolorenzo,et al.  Multicentre Clinical Trial with Herpes Simplex Virus Vaccine in Recurrent Herpes Infection , 1995, International journal of STD & AIDS.

[111]  J. Zeh,et al.  Virologic characteristics of subclinical and symptomatic genital herpes infections. , 1995, The New England journal of medicine.

[112]  M. Khayyami,et al.  Human leukocyte interferon-alpha in cream for the treatment of genital herpes in Asian males. A placebo-controlled, double-blind study. , 1995, Dermatology.

[113]  C. Dekker,et al.  A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy , 1995, Annals of Internal Medicine.

[114]  V. Vonka,et al.  Increased effects of topically applied interferon on herpes simplex virus-induced lesions by caffeine. , 1995, Acta virologica.

[115]  K. Weismann,et al.  Quercetin and kaempherol: an argument against the use of podophyllin? , 1995, Genitourinary medicine.

[116]  B. Savarese,et al.  Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes , 1994, The Lancet.

[117]  M. Stoler,et al.  Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. , 1994, The American journal of medicine.

[118]  K. Weismann,et al.  Topical tromantadine in the treatment of genital herpes. A double-blind placebo controlled study. , 1993, Danish medical bulletin.

[119]  L. Goldberg,et al.  Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group. , 1993, Archives of dermatology.

[120]  D. Margolis,et al.  Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. , 1993, The Journal of infectious diseases.

[121]  L. Goldberg,et al.  Long-term Suppression of Recurrent Genital Herpes With Acyclovir: A 5-Year Benchmark , 1993 .

[122]  K. Rittweger,et al.  Recurrence of condylomata acuminata following cryotherapy is not prevented by systemically administered interferon. , 1993, Genitourinary medicine.

[123]  M. Lebwohl,et al.  Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis. , 1992, Antiviral research.

[124]  L. Corey,et al.  Risk Factors for the Sexual Transmission of Genital Herpes , 1992, Annals of Internal Medicine.

[125]  M. Velasco,et al.  [Prolonged treatment with acyclovir in recurrent genital herpes. Clinical, virological, and immunological response]. , 1991, Revista medica de Chile.

[126]  W. Dinsmore,et al.  Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study. , 1991, Genitourinary medicine.

[127]  R. Elswick,et al.  A Double-Blind, Randomized Trial of 0.5% Podofilox and Placebo for the Treatment of Genital Warts in Women , 1991, Obstetrics and gynecology.

[128]  M. Walzman,et al.  Treatment of External Genital Warts Comparing Cryotherapy (Liquid Nitrogen) and Trichloracetic Acid , 1991, Sexually transmitted diseases.

[129]  C. Petersen,et al.  Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. , 1991, Genitourinary medicine.

[130]  R. Damstra,et al.  Cryotherapy in the treatment of condylomata acuminata: a controlled study of 64 patients. , 1991, The Journal of dermatologic surgery and oncology.

[131]  C. Crumpacker,et al.  Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection , 1991, JAMA.

[132]  L. Corey,et al.  Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. , 1990, The American journal of medicine.

[133]  L. Corey,et al.  Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. , 1990, The Journal of infectious diseases.

[134]  S. Sacks,et al.  Randomized, double-blind, placebo-controlled, patient-initiated study of topical high-and low-dose interferon-α with nonoxynol-9 in the treatment of recurrent genital herpes , 1990 .

[135]  A. Hadgu,et al.  Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. , 1990, Genitourinary medicine.

[136]  G. Scambia,et al.  Randomized Clinical Trial Comparing Systemic Interferon With Diathermocoagulation in Primary Multiple and Widespread Anogenital Condyloma , 1989, Obstetrics and gynecology.

[137]  C. Petersen,et al.  Oral acyclovir suppressive therapy in severe recurrent genital herpes. A double-blind, placebo-controlled cross-over study. , 1989, Danish medical bulletin.

[138]  R. Thisted,et al.  PATIENT-APPLIED PODOFILOX FOR TREATMENT OF GENITAL WARTS , 1989, The Lancet.

[139]  E. Laerum,et al.  [Acyclovir creme in recurrent herpes genitalis]. , 1989, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[140]  E. Lunenfeld,et al.  [Beta-interferon for labial and genital herpes virus infection]. , 1989, Harefuah.

[141]  G. Krueger,et al.  Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind, placebo-controlled trial. , 1988, Annals of internal medicine.

[142]  S. Lemon,et al.  Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. , 1988, JAMA.

[143]  R. Reid,et al.  Genital condylomas in pregnancy: use of trichloroacetic acid and laser therapy. , 1988, American journal of obstetrics and gynecology.

[144]  A. Mindel,et al.  DOSAGE AND SAFETY OF LONG-TERM SUPPRESSIVE ACYCLOVIR THERAPY FOR RECURRENT GENITAL HERPES , 1988, The Lancet.

[145]  E. Lunenfeld,et al.  PLACEBO-CONTROLLED TRIAL OF TOPICAL INTERFERON IN LABIAL AND GENITAL HERPES , 1988, The Lancet.

[146]  H. Stiver,et al.  Chronic Suppression for Six Months Compared With Intermittent Lesional Therapy of Recurrent Genital Herpes Using Oral Acyclovir: Effects on Lesions and Nonlesional Prodromes , 1988, Sexually transmitted diseases.

[147]  M. Gellan,et al.  Cryotherapy compared with trichloroacetic acid in treating genital warts. , 1987, Genitourinary medicine.

[148]  A. Lassus.  COMPARISON OF PODOPHYLLOTOXIN AND PODOPHYLLIN IN TREATMENT OF GENITAL WARTS , 1987, The Lancet.

[149]  Y. Bryson,et al.  Suppression of Recurrent Genital Herpes Simplex Virus Infection with Recombinant α2 Interferon , 1986 .

[150]  G. Kinghorn,et al.  Efficacy of combined treatment with oral and topical acyclovir in first episode genital herpes. , 1986, Genitourinary medicine.

[151]  G. Kinghorn,et al.  Acyclovir prophylaxis of recurrent genital herpes: randomised placebo controlled crossover study. , 1985, Genitourinary medicine.

[152]  E. Sandström,et al.  Treatment of recurrent genital herpes simplex infections with oral acyclovir. , 1985, The Journal of antimicrobial chemotherapy.

[153]  D. Jeffries,et al.  Recurrent genital herpes suppressed by oral acyclovir: a multicentre double blind trial. , 1985, The Journal of antimicrobial chemotherapy.

[154]  G. Altomare,et al.  [Tromantadine hydrochloride in the treatment of herpes genitalis. A double-blind controlled study]. , 1985, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[155]  J. de Braekeleer,et al.  Clinical efficacy of a herpes simplex subunit vaccine , 1985, Journal of medical virology.

[156]  J. D. Christensen,et al.  Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. , 1985, Genitourinary medicine.

[157]  T. Hovi,et al.  Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study. , 1985, Acta dermato-venereologica.

[158]  G. Kinghorn,et al.  Recurrences after first episodes of genital herpes in patients treated with topical acyclovir cream. , 1984, Antiviral research.

[159]  G. Badger,et al.  Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. , 1984, JAMA.

[160]  D. Hindley,et al.  PROPHYLACTIC ORAL ACYCLOVIR IN RECURRENT GENITAL HERPES , 1984, The Lancet.

[161]  D. Alling,et al.  Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. , 1984 .

[162]  L. Corey,et al.  A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. , 1984, The New England journal of medicine.

[163]  C. Woodman,et al.  Efficacy of vaccine Ac NFU1 (S-) MRC 5 given after an initial clinical episode in the prevention of herpes genitalis. , 1983, The British journal of venereal diseases.

[164]  J. Cherry,et al.  Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. , 1983, The New England journal of medicine.

[165]  R. Thin,et al.  Topical acyclovir in the treatment of initial genital herpes. , 1983, The British journal of venereal diseases.

[166]  A. Nilsen,et al.  EFFICACY OF ORAL ACYCLOVIR IN THE TREATMENT OF INITIAL AND RECURRENT GENITAL HERPES , 1982, The Lancet.

[167]  K. Holmes,et al.  Ineffectiveness of topical idoxuridine in dimethyl sulfoxide for therapy for genital herpes. , 1982, JAMA.

[168]  K. Holmes,et al.  Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections. , 1982, The American journal of medicine.

[169]  A. Nilsen,et al.  Oral acyclovir in the treatment of genital herpes. Preliminary report of a multicenter trial. , 1982, The American journal of medicine.

[170]  G. Badger,et al.  Controlled trial of oral acyclovir in the therapy of recurrent herpes simplex genitalis. A preliminary report. , 1982, The American journal of medicine.

[171]  K. Holmes,et al.  A trial of topical acyclovir in genital herpes simplex virus infections. , 1982, The New England journal of medicine.

[172]  K. Leslie,et al.  The bone marrow in systemic podophyllin toxicity. , 1982, American journal of clinical pathology.

[173]  R. Thin,et al.  Cryotherapy versus electrocautery in the treatment of genital warts. , 1981, The British journal of venereal diseases.

[174]  E. Kern,et al.  Sensitivity of herpes simplex virus types 1 and 2 to three preparations of human interferon. , 1980, The Journal of infectious diseases.

[175]  M. Sá,et al.  Podophyllum toxicity: case report and literature review. , 1979 .

[176]  R. Russell,et al.  Treatment of Perianal and Anal Condylomata Acuminata: A New Operative Technique , 1978, Journal of the Royal Society of Medicine.

[177]  H. Weitgasser.  [Controlled clinical study of the herpes antigens LUPIDON H and LUPIDON G]. , 1977, Zeitschrift fur Hautkrankheiten.

[178]  G. Rüdiger,et al.  [Results of treatment with the Herpes simplex antigen Lupidon H, resp. Lupidon G]. , 1975, Zeitschrift fur Hautkrankheiten.

[179]  Bellet Re,et al.  Letter: ICRF 159. , 1974 .

[180]  Shipman Jj.  SELECTIVE FRONTAL LEUCOTOMY. , 1964 .

[181]  B. Schiff,et al.  VACCINE THERAPY IN RECURRENT HERPES SIMPLEX. , 1964, Archives of dermatology.

[182]  G. R. Girdlestone,et al.  Tuberculosis of bones and joints. , 1947, British medical journal.

[183]  S. Frank.  Formolized Herpes Virus Therapy and the Neutralizing Substance in Herpes Simplex1 , 1938 .

[184]  Takashi Kawana,et al.  [Genital herpes]. , 2009, Nihon rinsho. Japanese journal of clinical medicine.

[185]  Abeer Attia,et al.  Pulsed dye laser versus podophyllin resin in treatment of female genital warts , 2007 .

[186]  C. Perry,et al.  Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. , 2007, Drugs.

[187]  Edson Duarte Moreira Júnior,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.

[188]  A. Palazzo,et al.  Regression rate of clinical HPV infection of the lower genital tract during pregnancy after laser CO2 surgery. , 2006, Clinical and experimental obstetrics & gynecology.

[189]  F. Aoki,et al.  Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[190]  S. Tyring,et al.  Single-Day Therapy for Recurrent Genital Herpes , 2006, American journal of clinical dermatology.

[191]  S. Wallenstein,et al.  PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. , 2006, The Journal of infectious diseases.

[192]  E. Erbelding.  Glycoprotein D-adjuvant vaccine to prevent genital herpes. , 2003, Current infectious disease reports.

[193]  P. Sánchez,et al.  Acyclovir suppression to prevent recurrent genital herpes at delivery. , 2002, Infectious diseases in obstetrics and gynecology.

[194]  F. Aoki,et al.  Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. , 2000, AIDS.

[195]  M. Greenberg,et al.  Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. , 1998, Archives of dermatology.

[196]  A. Ferenczy,et al.  Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. , 1998, Archives of dermatology.

[197]  A. Ferenczy,et al.  Treating vaginal and external anogenital condylomas with electrosurgery vs CO2 laser ablation. , 1995, Journal of gynecologic surgery.

[198]  C. Dekker,et al.  A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. , 1995, Annals of internal medicine.

[199]  S. Lundin,et al.  Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of condylomata acuminata in women. A placebo-controlled, double-blind study. , 1994, Dermatology.

[200]  D. Baker.  Long-term suppressive therapy with acyclovir for recurrent genital herpes. , 1994, The Journal of international medical research.

[201]  L. Goldberg,et al.  Continuous five‐year treatment of patients with frequently recurring genital herpes simplex virus infection with acyclovir , 1993, Journal of medical virology.

[202]  E. DeLong,et al.  Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes. , 1990, The Journal of infectious diseases.

[203]  M. Stiller,et al.  Topical alpha-interferon in recurrent genital herpes simplex infection. A double-blind, placebo-controlled clinical trial. , 1990, Dermatologica.

[204]  Y. Bryson,et al.  Suppression of recurrent genital herpes simplex virus infection with recombinant alpha 2 interferon. , 1986, The Journal of infectious diseases.

[205]  L. Molin,et al.  Long-term oral acyclovir treatment prevents recurrent genital herpes. , 1986, Dermatologica.

[206]  D. Richman,et al.  DOUBLE BLIND PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR IN FIRST EPISODE GENITAL HERPES SIMPLEX VIRUS INFECTION , 1985 .

[207]  D. Goldmeier,et al.  Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy. , 1983, The Journal of antimicrobial chemotherapy.

[208]  L. Corey,et al.  Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. , 1983, The Journal of antimicrobial chemotherapy.

[209]  Y. Bryson.  Current status and prospects for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus. , 1983, The Journal of antimicrobial chemotherapy.

[210]  K. Nechev,et al.  Immunotherapy with inactivated polyvalent herpes vaccines. , 1982, Developments in biological standardization.

[211]  C. Woodman,et al.  Early experience with "antigenoid" vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis. , 1982, Developments in biological standardization.

[212]  L. M. Moher,et al.  Podophyllum toxicity: case report and literature review. , 1979, The Journal of family practice.

[213]  P. Cotton.  Endoscopic treatnent of biliary-tract diseases. , 1979, Lancet.

[214]  M. Ahumada.  [The effectiveness of tromantadine in herpes simplex: double-blind study]. , 1977, Therapie der Gegenwart.

[215]  J. D. Parker.  A double-blind trial of idoxuridine in recurrent genital herpes. , 1977, The Journal of antimicrobial chemotherapy.

[216]  Parker Jd.  A double-blind trial of idoxuridine in recurrent genital herpes. , 1977 .